MedTrace Logo

Evaluation of Reporting of AdVerse Events Associated With AnTicAncer theRapy (AVATAR)

NCT04696250 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 5000000

Last updated 2021-01-06

No results posted yet for this study

Summary

Anticancer drugs can lead to various adverse events. This study analyses reports of adverse events for treatment including Anatomical Therapeutic Chemical (ATC) classification L (antineoplastic agents, endocrine therapy, immunostimulants, and immunosuppressants drugs) in the World Health Organization's (WHO) global database of individual safety case reports (VigiBase).

Conditions

Interventions

DRUG

Antineoplastic and Immunomodulating Agents

Antineoplastic agents, endocrine therapy, immunostimulants and immunosuppressants drugs included in the ATC classification L

Sponsors & Collaborators

  • University Hospital, Caen

    lead OTHER

Eligibility

Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2021-01-01
Completion
2025-01-01
FDA Drug
Yes

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04696250 on ClinicalTrials.gov